Select Country

 
877-783-6728 (877-StemSave)

StemSave Blog

Multiple Sclerosis Treatment Utilizes The Patient’s Own Stem Cells

Posted by devin@stemsave.com on Oct 12, 2015 3:30:00 PM

Researchers at the Colorado Blood Cancer Institute have devised a successful, long-term treatment for relapsing/remitting multiple sclerosis (RRMS). The treatment approach seeks to ‘reboot’ the patient’s immune system by effectively erasing it and then rebooting it using the patient’s own [autologous] stem cells.  The treatment resulted in a disease reversal rate of 86% and halted progression rate of 91% in patients participating in the study. Study patients underwent immunosuppressive therapy for up to four weeks, after which autologous stem cells were re-infused to restore a healthy immune systems. Patients were then followed for up to five years.

Read More

Topics: multiple sclerosis, stemsaveblog, autologousstemcells, immune system, autoimmune attack, regenerative medicine

Crohn’s Fistula Relieved by Mesenchymal Stem Cells [MSCs].

Posted by anna@stemsave.com on Apr 23, 2015 3:26:15 PM

In a newly published phase II clinical trial from the Asan Medical Center in Seoul, Korea, researchers observed full recovery from fistulas [abnormal connections between organs caused by the inflammation] in 75% of patients suffering from Crohn’s disease upon the injection of autologous [the patient’s own] stem cells.  MSCs have the ability to regulate the patient’s immune system to reduce inflammation, resulting in the complete closure of the fistulas without recurrence.

Read More

Topics: large intestine, bank dental stem cells, Crohn's Disease, autologousstemcells, autoimmune disease, gastrointestinal disease, autoimmune attack, research, StemSave, mesenchymal stem cells, organs, stem cells, Fistulas

Multiple Sclerosis Treatment “Resets” Immune System through Stem Cell Transplantation.

Posted by maxi@stemsave.com on Apr 4, 2015 11:36:00 AM

In a recently published study, a team of researchers led by Dr. Giovanni Mancardi from the University of Genoa conducted a phase II clinical trial to compare the effectiveness of conventional multiple sclerosis [MS] therapy to intravenous stem cell transplantation.  Throughout the four year trial, the team found that, in addition to significantly decreasing disease progression and brain damage compared to MS drug mitoxantrone [MTX], the transplanted stem cells had migrated into the patients’ bone marrow and stimulated the generation of new, non-harmful immune cells, essentially resetting the immune system.

Read More

Topics: multiple sclerosis, stemsaveblog, Brain, clinical trials, clinical trial, bone marrow, immune system, neurological disease,, university of genoa,, autoimmune attack, nerve stem cells,

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

Subscribe to Email Updates

Join our Newsletter

Posts by Topic

see all